Akane Sada
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Akane Sada has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Rieko Ohki
Laboratory of Fundamental Oncology National Cancer Center Research Institute Tokyo Japan
2 shared publications - Yu Chen
Laboratory of Fundamental Oncology, National Cancer Center Research Institute
2 shared publications - Yuko Tabata
Laboratory of Fundamental Oncology, National Cancer Center Research Institute
2 shared publications Akihiko Yokoyama
Tsuruoka Metabolomics Laboratory, National Cancer Center
1 shared publication- Atsushi Kaneda
Department of Molecular Oncology, Graduate School of Medicine, Chiba University
1 shared publication - Kazuhiro Okumura
Division of Experimental Animal Research, Cancer Genome Center, Chiba Cancer Center Research Institute, Chiba, Japan
1 shared publication
Latest Publications
- Open Access
Metabolic intervention by low carbohydrate diet suppresses the onset and progression of neuroendocrine tumors
Insulin signaling often plays a role in the regulation of cancer including tumor initiation, progression, and response to treatment. In addition, the insulin-regulated PI3K-Akt-mTOR pathway plays an important role in the regulation of islet cell proliferation and this pathway is hyperactivated in human non-functional pancreatic neuroendocrine tumors (PanNETs). We therefore investigated the effect of a very low carbohydrate diet (ketogenic diet) on a mouse model that develops non-functional PanNETs to ask how reduced PI3K-Akt-mTOR signaling might affect the development and progression of non-functional PanNET. We found that this dietary intervention resulted in lower PI3K-Akt-mTOR signaling in islet cells and a significant reduction in PanNET formation and progression. We also found that this treatment had a significant effect on the suppression of pituitary NET development. Furthermore, we found that non-functional PanNET patients with lower blood glucose levels tend to have a better prognosis than patients with higher blood glucose levels. This preclinical study shows that a dietary intervention that results in lower serum insulin levels leads to lower insulin signal within the neuroendocrine cells and has a striking suppressive effect on the development and progression of both pancreatic and pituitary NETs.
Open AccessMetabolic intervention by low carbohydrate diet suppresses the onset and progression of neuroendocrine tumors
Insulin signaling often plays a role in the regulation of cancer including tumor initiation, progression, and response to treatment. In addition, the insulin-regulated PI3K-Akt-mTOR pathway plays an important role in the regulation of islet cell proliferation and this pathway is hyperactivated in human non-functional pancreatic neuroendocrine tumors (PanNETs). We therefore investigated the effect of a very low carbohydrate diet (ketogenic diet) on a mouse model that develops non-functional PanNETs to ask how reduced PI3K-Akt-mTOR signaling might affect the development and progression of non-functional PanNET. We found that this dietary intervention resulted in lower PI3K-Akt-mTOR signaling in islet cells and a significant reduction in PanNET formation and progression. We also found that this treatment had a significant effect on the suppression of pituitary NET development. Furthermore, we found that non-functional PanNET patients with lower blood glucose levels tend to have a better prognosis than patients with higher blood glucose levels. This preclinical study shows that a dietary intervention that results in lower serum insulin levels leads to lower insulin signal within the neuroendocrine cells and has a striking suppressive effect on the development and progression of both pancreatic and pituitary NETs.
- 1 April 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 142 (4) , 1040-1049.e8
PHLDA3 Is an Important Downstream Mediator of p53 in Squamous Cell Carcinogenesis
- 1 April 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 142 (4) , 1040-1049.e8
PHLDA3 Is an Important Downstream Mediator of p53 in Squamous Cell Carcinogenesis